JP2023512441A5 - - Google Patents
Info
- Publication number
- JP2023512441A5 JP2023512441A5 JP2022542475A JP2022542475A JP2023512441A5 JP 2023512441 A5 JP2023512441 A5 JP 2023512441A5 JP 2022542475 A JP2022542475 A JP 2022542475A JP 2022542475 A JP2022542475 A JP 2022542475A JP 2023512441 A5 JP2023512441 A5 JP 2023512441A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- optionally
- antisense strand
- nucleoside
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025207980A JP2026062645A (ja) | 2020-01-10 | 2025-11-28 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959590P | 2020-01-10 | 2020-01-10 | |
| US202062959469P | 2020-01-10 | 2020-01-10 | |
| US202062959398P | 2020-01-10 | 2020-01-10 | |
| US62/959,398 | 2020-01-10 | ||
| US62/959,590 | 2020-01-10 | ||
| US62/959,469 | 2020-01-10 | ||
| PCT/US2021/012650 WO2021142227A1 (en) | 2020-01-10 | 2021-01-08 | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207980A Division JP2026062645A (ja) | 2020-01-10 | 2025-11-28 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512441A JP2023512441A (ja) | 2023-03-27 |
| JP2023512441A5 true JP2023512441A5 (enExample) | 2024-01-17 |
Family
ID=76788282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542475A Pending JP2023512441A (ja) | 2020-01-10 | 2021-01-08 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
| JP2025207980A Pending JP2026062645A (ja) | 2020-01-10 | 2025-11-28 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207980A Pending JP2026062645A (ja) | 2020-01-10 | 2025-11-28 | 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230111147A1 (enExample) |
| EP (1) | EP4087586A4 (enExample) |
| JP (2) | JP2023512441A (enExample) |
| CN (1) | CN115335062A (enExample) |
| CA (1) | CA3163283A1 (enExample) |
| WO (1) | WO2021142227A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4169576A1 (en) | 2018-03-23 | 2023-04-26 | University of Massachusetts | Gene therapeutics for treating bone disorders |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| JP7780691B2 (ja) * | 2020-01-10 | 2025-12-05 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
| AU2021206234A1 (en) * | 2020-01-10 | 2022-09-01 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US20250057971A1 (en) | 2021-12-22 | 2025-02-20 | Sapreme Technologies B.V. | Targeted saponin-nucleic acid conjugates for treatment of muscle wasting disorders |
| WO2023121444A1 (en) | 2021-12-22 | 2023-06-29 | Sapreme Technologies B.V. | Compositions comprising therapeutic nucleic acid and targeted saponin for the treatment of muscle-wasting disorders |
| JP2025500481A (ja) | 2021-12-22 | 2025-01-09 | サプリーム テクノロジーズ，ベー．フェー． | 筋消耗性障害を治療するための治療用核酸とサポニンとを含む組成物 |
| WO2023201318A1 (en) * | 2022-04-15 | 2023-10-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
| IL316143A (en) | 2022-04-15 | 2024-12-01 | Dyne Therapeutics Inc | Muscle targeting complexes and formulations for the treatment of myotonic dystrophy |
| WO2023230562A2 (en) * | 2022-05-26 | 2023-11-30 | Board Of Regents Of The University Ofnebraska | Rna compositions and therapeutic methods thereof |
| EP4698654A1 (en) * | 2023-04-20 | 2026-02-25 | University of Massachusetts | Rnas targeting activin a subunits |
| WO2024220863A1 (en) * | 2023-04-20 | 2024-10-24 | University Of Massachusetts | Rna therapeutics for fibrodysplasia ossificans progressiva and uses thereof |
| WO2025160275A1 (en) | 2024-01-24 | 2025-07-31 | Arrowhead Pharmaceuticals, Inc. | Anti-transferrin receptor antibodies, conjugates thereof, and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007104971A (ja) * | 2005-10-14 | 2007-04-26 | New Industry Research Organization | ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド |
| WO2009126913A1 (en) * | 2008-04-11 | 2009-10-15 | Cedars-Sinai Medical Center | Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery |
| GB0904214D0 (en) * | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| CA2818173C (en) * | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| US10004814B2 (en) * | 2013-11-11 | 2018-06-26 | Sirna Therapeutics, Inc. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
| CN103882024A (zh) * | 2014-04-21 | 2014-06-25 | 石河子大学 | 一种RNAi干扰片段、RNAi干扰载体及其应用 |
| US10508151B2 (en) * | 2014-11-19 | 2019-12-17 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| DK3473270T5 (da) * | 2016-06-20 | 2024-09-09 | Genahead Bio Inc | Konjugat af antistof-lægemiddel |
| WO2018057575A1 (en) * | 2016-09-21 | 2018-03-29 | Alnylam Pharmaceuticals, Inc | Myostatin irna compositions and methods of use thereof |
| KR102497564B1 (ko) * | 2016-12-26 | 2023-02-07 | 제이씨알 파마 가부시키가이샤 | 혈액뇌관문을 통과하는 신규한 항인간 트랜스페린 수용체 항체 |
| AU2018378812B2 (en) * | 2017-12-06 | 2025-05-22 | Avidity Biosciences, Inc. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
| IL276327B2 (en) * | 2018-02-05 | 2024-05-01 | Japan Chem Res | Method for delivering drug to muscle |
| WO2020028836A1 (en) * | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
-
2021
- 2021-01-08 CA CA3163283A patent/CA3163283A1/en active Pending
- 2021-01-08 WO PCT/US2021/012650 patent/WO2021142227A1/en not_active Ceased
- 2021-01-08 CN CN202180018131.0A patent/CN115335062A/zh active Pending
- 2021-01-08 EP EP21738475.9A patent/EP4087586A4/en active Pending
- 2021-01-08 JP JP2022542475A patent/JP2023512441A/ja active Pending
- 2021-01-08 US US17/791,670 patent/US20230111147A1/en active Pending
-
2025
- 2025-11-28 JP JP2025207980A patent/JP2026062645A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512441A5 (enExample) | ||
| JP2023510351A5 (enExample) | ||
| JP2023512442A5 (enExample) | ||
| JP2023509793A5 (enExample) | ||
| JP2024501872A5 (enExample) | ||
| JP2021533199A5 (enExample) | ||
| JP2022513482A5 (enExample) | ||
| JP2023510350A5 (enExample) | ||
| JP2023535078A5 (enExample) | ||
| JP2023535073A5 (enExample) | ||
| JP2021533200A5 (enExample) | ||
| JP7803926B2 (ja) | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 | |
| JP2021532832A5 (enExample) | ||
| JP2021533197A5 (enExample) | ||
| JP2024524222A5 (enExample) | ||
| JP2022122928A5 (enExample) | ||
| IL274906B2 (en) | Compositions and methods for treating muscular dystrophy and myotonic dystrophy | |
| JP2023535444A5 (enExample) | ||
| JP2025067909A5 (enExample) | ||
| IL317871A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
| JP2020505330A5 (enExample) | ||
| JP2024527362A5 (enExample) | ||
| JP2024535797A5 (enExample) | ||
| JP2021533198A5 (enExample) | ||
| IL319265A (en) | Anti-transferrin receptor antibodies and their uses |